Abstract
Spasticity is a motor disorder with an increased muscle tone, typically associated with spasms, weakness and lack of coordination. It is an invalidating and debilitating pathology, characterized by pain, limited autonomy in activities of daily living, development of severe lesions. Spasticity can be adequately treated with physiotherapy, muscle relaxants drugs or topical treatment with botulinic toxin type A. Intrathecal baclofen therapy is very effective in the treatment of severe and generalized spasticity. Sometimes, soft tissues adjacent to the implant intrathecal infusion become infected; removing intrathecal infusion and systemic antibiotic therapy are best solution for clinical cure. However, removing intrathecal baclofen therapy could increase muscle spasticity with enhancement of pain and clonus that can worsen quality of life. In this study, we evaluated clinical improvement after complete healing of the septic focus and implantation of a new infuser.
MeSH terms
-
Abdomen
-
Administration, Oral
-
Adolescent
-
Anti-Bacterial Agents / therapeutic use
-
Baclofen / administration & dosage*
-
Baclofen / therapeutic use
-
Catheter-Related Infections / complications*
-
Catheter-Related Infections / drug therapy
-
Catheter-Related Infections / microbiology
-
Device Removal
-
Dose-Response Relationship, Drug
-
Drug Monitoring
-
GABA-B Receptor Agonists / administration & dosage*
-
GABA-B Receptor Agonists / therapeutic use
-
Humans
-
Infusion Pumps
-
Infusion Pumps, Implantable / adverse effects*
-
Infusions, Spinal / adverse effects*
-
Intellectual Disability / complications
-
Male
-
Quadriplegia / complications
-
Quadriplegia / drug therapy*
-
Quadriplegia / physiopathology
-
Reoperation
-
Sepsis / complications*
-
Sepsis / drug therapy
-
Sepsis / microbiology
-
Severity of Illness Index
-
Soft Tissue Infections / complications
-
Soft Tissue Infections / drug therapy
-
Soft Tissue Infections / microbiology
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
GABA-B Receptor Agonists
-
Baclofen